✦ LIBER ✦

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

✍ Scribed by Ernst-Wilhelm Radue; William H. Stuart; Peter A. Calabresi; Christian Confavreux; Steven L. Galetta; Richard A. Rudick; Fred D. Lublin; Bianca Weinstock-Guttman; Daniel R. Wynn; Elizabeth Fisher; Athina Papadopoulou; Frances Lynn; Michael A. Panzara; Alfred W. Sandrock

Book ID: 119303680
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 256 KB
Volume: 292
Category: Article
ISSN: 0022-510X
DOI: 10.1016/j.jns.2010.02.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Natalizumab vs interferon beta 1a in rel

Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study

✍ R. Lanzillo; M. Quarantelli; S. Bonavita; G. Ventrella; G. Lus; G. Vacca; A. Pri 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB

Intramuscular interferon beta-1a for dis

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis

✍ Dr. Lawrence D. Jacobs; Diane L. Cookfair; Richard A. Rudick; Robert M. Herndon; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 980 KB

Long-term clinical experience with weekl

Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis

✍ G. Coppola; R. Lanzillo; C. Florio; G. Orefice; P. Vivo; S. Ascione; V. Schiavon 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 522 KB

Rationale for early treatment with inter

Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis

✍ Frederick E. Munschauer III; William H. Stuart 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 942 KB

5-31-07 Interferon beta 1a in the treatm

5-31-07 Interferon beta 1a in the treatment of relapsing/remitting multiple sclerosis

✍ Ljapcev, R.; Gogovska, L.; Tanovska, M. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 180 KB

OPL102 Subgroup analyses from SENTINEL:

OPL102 Subgroup analyses from SENTINEL: a randomized controlled trial of natalizumab (Tysabri®) and interferon beta-1a (AVONEX®) in relapsing multiple sclerosis (MS)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB